# Bumetanide in Patients With Alzheimer's Disease

> **NCT06052163** · PHASE2 · RECRUITING · sponsor: **Stanford University** · enrollment: 40 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Bumetanide
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06052163
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-10
- **Primary completion:** 2026-12-15
- **Final completion:** 2026-12-15
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-01-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06052163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06052163, "Bumetanide in Patients With Alzheimer's Disease". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT06052163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*